HOUSTON, May 4, 2016 /PRNewswire/ -- SpinalCyte, LLC, a Texas-based tissue engineering technology company focused on regrowth of the spinal disc nucleus using human dermal fibroblasts, announced today the issuance of U.S. Patent No. 9,320,776, "Methods And Compositions For Repair Of Cartilage Using An In Vivo Bioreactor." The technology described in the patent involves a device which is a resorbable and biodegradable structure that can be permeable to oxygen but hermetic to fluids. Also claimed in the patent is the device having outer biodegradable membrane that encompasses nutrients and/or growth factors.
"This new patent broadens our portfolio of unique intellectual property which will further advance our leading position in human dermal fibroblast regeneration of tissue. Our current portfolio includes 12 U.S. and foreign patents issued and directly owned by the company, along with 38 patents pending," said Pete O'Heeron, Chief Executive Officer for SpinalCyte.
About SpinalCyte, LLC
Based in Houston, Texas, SpinalCyte, LLC is a tissue engineering technology company founded for the purpose of developing an innovative solution for spinal nucleus replacement using human dermal fibroblasts. To date, SpinalCyte has been funded entirely by angel investors.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spinalcyte-llc-receives-new-united-states-patent-for-spinal-disc-tissue-engineering-300262156.html
SOURCE SpinalCyte, LLC